PROKIDNEY CORP.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | During market hours | $150.00K | $-0.15 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 15, 2026 | Before market open | $226.00K | $-0.14 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 18, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | During market hours | $217.00K | $-0.12 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | During market hours | $221.00K | $-0.13 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | During market hours | $230.00K | $-0.13 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 17, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | $-0.14 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 9, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 10, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 22, 2024 | After market close | – | – | – |
Press releases
Announcements Prokidney filed with the SEC
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Transforming the Future of Chronic Kidney Disease Treatment Corporate Presentation May 2026 Preserving Kidney Function in Patients at High Risk of Kidney Failure Exhibit 99.2
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
ProKidney Reports Full Year 2025 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Transforming the Future of Chronic Kidney Disease Treatment Corporate Presentation February 2026 Preserving Kidney Function in Patients at High Risk of Kidney Failure Exhibit 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Transforming the Future of Chronic Kidney Disease Treatment Corporate Presentation January 2026 Preserving Kidney Function in Patients at High Risk of Kidney Failure Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
Results of operations · EX-99.1 to Form 8-K
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
Results of operations · EX-99.1 to Form 8-K
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
March 2024 July 2025 Corporate
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
Regulation FD disclosure · EX-99.1 to Form 8-K
March 2024 July 2025 Corporate Presentation Exhibit 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware
Regulation FD disclosure · EX-99.1 to Form 8-K
ProKidney Reports First Quarter 2025 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
ProKidney Reports Full Year 2024 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Results of operations · EX-99.1 to Form 8-K
Developing Solutions for Dialysis Prevention September 2024 Corporate Presentation Exhibit 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct
Material agreement · Other events · EX-99.1 to Form 8-K
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Developing Solutions for Dialysis Prevention REGEN-007 Interim Results
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
RMCL-002 Final Analysis Developing Solutions for Dialysis Prevention May 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
for Dialysis Prevention REACT® [REnal Autologous Cell Therapy]
Regulation FD disclosure · EX-99.1 to Form 8-K
ProKidney Reports Third Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Developing Solutions for Dialysis Prevention REACT® [REnal Autologous Cell Therapy]
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT ® ) for Diabetic CKD and Provides Corporate Updates
Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Corporate Presentation September 2023 Exhibit 99.1 PROKIDNEY. A Step Closer to Potential Dialysis Prevention REACT® [REnal Autologous Cell Therapy]
Regulation FD disclosure · EX-99.1 to Form 8-K
ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC
Other events · EX-99.1 to Form 8-K
ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights
Results of operations · EX-99 to Form 8-K
J.P. Morgan Investor Conference January 2023 Exhibit 99.1 PROKIDNEY A Step Closer to Potential Dialysis Prevention REACT® [REnal Autologous Cell Therapy]
Regulation FD disclosure · EX-99.1 to Form 8-K
ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Renal Autologous Cell Therapy September 2022 A Step Closer to Potential Dialysis Prevention ProKidney Corp. Nasdaq: PROK
Regulation FD disclosure · EX-99.1 to Form 8-K